Novartis latest In line to shut down brain research facility as pharmaceutical companies look to investigate alternative avenues

摘要

Following similar moves by GlaxoSmithKline and AstraZeneca, Swiss-based drug giant Novartis has closed its neuroscience facility in Basel, Switzerland, The move signals the end of more traditional drug-discovery programs aimed at pursuing treatments for brain disorders. Other companies to similarly pull back on research into this area include US-based companies Pfizer and Merck, as well as Sanofi, based in France.